Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

All Eyes On Amjevita, Amgen’s Humira Biosimilar And Sole 2023 Product Launch

Dual Pricing Strategy Addresses Unique US Payer Priorities

Executive Summary

The company launched Amjevita on the same day it announced fourth quarter 2022 earnings and provided 2023 guidance, upping the high-profile nature of the first-to-market US Humira biosimilar.

You may also be interested in...



Costs From ICER’s Unsupported Price Increase List Tick Back Up

Humira topped ICER’s list of drugs with unsupported price increases that added the most cost to the US health care system during 2022, its last year before biosimilars hit the US market.

Amgen Absorbs Horizon, Pitches Plans For New Rare Disease Growth Engine

Now that Amgen has completed its $27.8bn acquisition of Horizon, the company can focus on how it will turn Tepezza back into a growth product and maintain momentum for Krystexxa and other assets.

AbbVie’s Immunology Growth Strategy Is Delivering, But Imbruvica Reduced By IRA

AbbVie’s $2.1bn write down of Imbruvica’s value is tied directly to Medicare drug price negotiations. Humira’s US biosimilar erosion continued as projected, while the Skyrizi/Rinvoq duo are set to top Humira peak sales by 2027.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147833

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel